Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Calquence by AstraZeneca for Graft Versus Host Disease (GVHD): Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD). According to...
Calquence by AstraZeneca for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...
Calquence by AstraZeneca for Anti-MAG Peripheral Neuropathy: Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Anti-MAG Peripheral Neuropathy. According to GlobalData, Phase...
Calquence by AstraZeneca for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According to...
Calquence by AstraZeneca for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...
Calquence by AstraZeneca for Follicular Lymphoma: Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase III...
Calquence by AstraZeneca for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid...
Calquence by AstraZeneca for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According to...
Calquence by AstraZeneca for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData,...